Streetbeat News

Analyst Ratings

ED

RBC Capital analyst Shelby Tucker maintains a Sector Perform rating on Consolidated Edison (NYSE:ED) and lowers the price target from $94 to $93.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:12 pm

CRBG

RBC Capital analyst Scott Heleniak has maintained an Outperform rating on Corebridge Financial (NYSE:CRBG) and increased the price target from $25 to $28.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:10 pm

DDOG

RBC Capital analyst Matthew Hedberg has reiterated an Outperform rating on Datadog (NASDAQ:DDOG) and maintained a price target of $151.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:08 pm

DLR

RBC Capital analyst Jonathan Atkin has reiterated an Outperform rating on Digital Realty Trust (NYSE:DLR), maintaining a price target of $144. This reaffirmation of the stock's potential indicates a positive outlook on its future performance.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:06 pm

DASH

RBC Capital analyst Brad Erickson maintains a Sector Perform rating on DoorDash (NASDAQ:DASH) and raises the price target from $105 to $130.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:03 pm

DCO

RBC Capital analyst Ken Herbert has reiterated an Outperform rating on Ducommun (NYSE:DCO) and maintained a $60 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:01 pm

GLUE

Wedbush initiated coverage on Monte Rosa Therapeutics on Thursday, Feb. 15, marking a significant event for the company and its investors.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:01 pm

ALNY

Goldman Sachs downgraded Alnylam Pharmaceuticals (NASDAQ:ALNY) from its previous rating to Neutral, adjusting the price target from $230.00 to $173.00. Despite the downgrade, ALNY shares have risen by 0.41% in the last 24 hours to $148.04. The new price target suggests a potential 16.86% increase from the current price. Alnylam is recognized for its pioneering work in RNA interference (RNAi) therapeutics, with five drugs on the market and several clinical programs across different therapeutic areas.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:00 pm

NKE

15 analysts have recently provided mixed ratings for Nike (NYSE:NKE), with a consensus 12-month price target of $122.67, reflecting a 1.45% increase from the previous target. The ratings range from 'Buy' to 'Neutral', with several analysts adjusting their price targets. Nike's financial overview shows a positive revenue trend, superior market capitalization, and strong financial health indicators such as net margin, ROE, and ROA. The company's prudent debt management is also highlighted.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:00 pm

PTEN

Raymond James has maintained its Strong Buy rating for Patterson-UTI Energy (NASDAQ:PTEN) but lowered its price target from $16.00 to $15.00. PTEN's shares are currently trading down at $11.71, indicating a potential 28.1% increase to the new target price. Patterson-UTI Energy operates as one of the largest land rig drilling contractors in the U.S., with operations primarily in Texas, the Appalachian region, and Colombia.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:00 pm